[go: up one dir, main page]

WO2011132077A3 - Diagnostic assay - Google Patents

Diagnostic assay Download PDF

Info

Publication number
WO2011132077A3
WO2011132077A3 PCT/IB2011/001014 IB2011001014W WO2011132077A3 WO 2011132077 A3 WO2011132077 A3 WO 2011132077A3 IB 2011001014 W IB2011001014 W IB 2011001014W WO 2011132077 A3 WO2011132077 A3 WO 2011132077A3
Authority
WO
WIPO (PCT)
Prior art keywords
target molecule
binding
molecules
sample
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2011/001014
Other languages
French (fr)
Other versions
WO2011132077A2 (en
Inventor
Socrates Tzartos
John Tzartos
Elissavet Tzartou
Nikolaos Trakas
Christos Stergiou
Paraskevi Zisimopoulou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hellenic Pasteur Institute
Original Assignee
Hellenic Pasteur Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hellenic Pasteur Institute filed Critical Hellenic Pasteur Institute
Priority to EP11724450A priority Critical patent/EP2561358A2/en
Publication of WO2011132077A2 publication Critical patent/WO2011132077A2/en
Publication of WO2011132077A3 publication Critical patent/WO2011132077A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A method of detecting the presence of a target molecule in a biological sample from a subject, wherein the target molecule is capable of binding to a binding molecule, wherein the method comprises the steps of: a) subjecting the biological sample to a purification step to provide an enriched target molecule sample, wherein the purification step comprises: i) contacting binding molecules with the biological sample to enable binding of the target molecules to the binding molecules, and ii) removing target molecules from the binding molecules to provide the enriched target molecule sample; and b) subjecting the enriched target molecule sample to an assay to detect the presence of the target molecule.
PCT/IB2011/001014 2010-04-21 2011-04-18 Diagnostic assay Ceased WO2011132077A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11724450A EP2561358A2 (en) 2010-04-21 2011-04-18 Diagnostic assay

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GR20100100240 2010-04-21
GR20100100240A GR1007341B (en) 2010-04-21 2010-04-21 Diagnostic assay

Publications (2)

Publication Number Publication Date
WO2011132077A2 WO2011132077A2 (en) 2011-10-27
WO2011132077A3 true WO2011132077A3 (en) 2012-05-18

Family

ID=44510129

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/001014 Ceased WO2011132077A2 (en) 2010-04-21 2011-04-18 Diagnostic assay

Country Status (3)

Country Link
EP (1) EP2561358A2 (en)
GR (1) GR1007341B (en)
WO (1) WO2011132077A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011011280A1 (en) * 2011-02-15 2012-08-16 Euroimmun Medizinische Labordiagnostika Ag Diagnostic kit and a method for examining a human patient sample for the presence of neuromyelitis optica-specific antibodies
DE102014226663A1 (en) * 2014-12-19 2016-06-23 Charité Universitätsmedizin Berlin Bridge assays for the detection of antibodies against members of the cardiac receptor family
CN119881293A (en) 2018-03-21 2025-04-25 沃特世科技公司 Non-antibody-based high affinity sample preparation, adsorbents, devices and methods
CN114487448B (en) * 2022-01-21 2022-10-18 天津天海新域生物科技有限公司 Composition and kit for detecting myasthenia gravis-related antibody and application of composition and kit

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004251A1 (en) * 1986-01-06 1987-07-16 The Salk Institute For Biological Studies Assays for myasthenia gravis and substrates and kits for use therein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4033722A (en) 1975-08-08 1977-07-05 The Salk Institute For Biological Studies Assay for myasthenia gravis
GB0014878D0 (en) 2000-06-16 2000-08-09 Isis Innovation Neurotransmission disorders
US7101679B2 (en) 2003-11-25 2006-09-05 Mayo Foundation For Medical Education And Research Marker for neuromyelitis optica

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004251A1 (en) * 1986-01-06 1987-07-16 The Salk Institute For Biological Studies Assays for myasthenia gravis and substrates and kits for use therein

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
C. GOTTI ET AL: "Detection of antibody classes and subpopulations in Myasthenia gravis patients using a new nonradioactive enzyme immunoassay", MUSCLE & NERVE, vol. 20, no. 7, 1 July 1997 (1997-07-01), pages 800 - 808, XP055006521, ISSN: 0148-639X, DOI: 10.1002/(SICI)1097-4598(199707)20:7<800::AID-MUS3>3.0.CO;2-B *
FRANCIOTTA D ET AL: "TE671 Cell-based ELISA for Anti-Acetylcholine Receptor Antibody Determination in Myasthenia Gravis", CLINICAL CHEMISTRY, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY, WASHINGTON, DC, vol. 45, no. 3, 1 January 1999 (1999-01-01), pages 400 - 405, XP003010471, ISSN: 0009-9147 *
HEWER R ET AL: "A sensitive non-isotopic assay for acetylcholine receptor autoantibodies", CLINICA CHIMICA ACTA, ELSEVIER BV, AMSTERDAM, NL, vol. 364, no. 1-2, 1 February 2006 (2006-02-01), pages 159 - 166, XP025058834, ISSN: 0009-8981, [retrieved on 20060201], DOI: 10.1016/J.CCCN.2005.05.035 *
LINDSTROM ET AL: "An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, SAN DIEGO, CA, US, vol. 7, no. 1, 1 January 1977 (1977-01-01), pages 36 - 43, XP026197852, ISSN: 0090-1229, [retrieved on 19770101], DOI: 10.1016/0090-1229(77)90027-7 *
M. I. LEITE ET AL: "IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis", BRAIN, vol. 131, no. 7, 1 July 2008 (2008-07-01), pages 1940 - 1952, XP055006523, ISSN: 0006-8950, DOI: 10.1093/brain/awn092 *
PSARIDI-LINARDAKI L ET AL: "Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit. Development of an antigen-specific therapeutic strategy", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, XX, vol. 159, no. 1-2, 1 February 2005 (2005-02-01), pages 183 - 191, XP004709564, ISSN: 0165-5728, DOI: 10.1016/J.JNEUROIM.2004.10.002 *
SOCRATES J. TZARTOS ET AL: "Antigen-specific Apheresis of Pathogenic Autoantibodies from Myasthenia Gravis Sera", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 1132, no. 1, 1 June 2008 (2008-06-01), pages 291 - 299, XP055006504, ISSN: 0077-8923, DOI: 10.1196/annals.1405.017 *

Also Published As

Publication number Publication date
WO2011132077A2 (en) 2011-10-27
EP2561358A2 (en) 2013-02-27
GR1007341B (en) 2011-07-05

Similar Documents

Publication Publication Date Title
WO2011150115A3 (en) Methods and apparatus for point-of-care detection of nucleic acid in a sample
WO2013157917A3 (en) A biosensor and preparation method thereof
WO2013050881A3 (en) Direct nucleic acid analysis
WO2011116006A3 (en) A rapid method to measure cyanide in biological samples
WO2005103298A3 (en) Method for detecting ncrna
CL2011002228A1 (en) Apparatus for the integrated analysis of nucleic acids in real time, and method of detection of said molecules.
WO2013144643A3 (en) Biosensor device and system
WO2011100708A3 (en) Assay card for sample acquisition, treatment and reaction
WO2007117832A3 (en) Methods of detecting target nucleic acids
HK1211260A1 (en) Method and kit for nucleic acid sequencing
WO2009121032A3 (en) Sample preparation devices and methods for processing analytes
WO2011022093A3 (en) Methods and devices for detecting the presence of an analyte in a sample
WO2007120265A3 (en) Coded molecules for detecting target analytes
WO2009060847A1 (en) Method and kit for preparation of sample for use in nucleic acid amplification
WO2011136624A3 (en) Automatic biological sample purification device having a magnetic-field-applying unit, a method for extracting a target substance from a biological sample, and a protein expression and purification method
WO2013040435A3 (en) Molecular diagnostic assay device and method of use
WO2010141075A8 (en) Specific analysis of ketone and aldehyde analytes using reagent compounds, labeling strategies, and mass spectrometry workflow
WO2010135574A3 (en) Systems and methods for determining the percentage of glycated hemoglobin
WO2011121454A3 (en) Direct nucleic acid analysis
EP2254897A4 (en) Methods, reagents and kits for detection of nucleic acid molecules
WO2009024726A3 (en) Method for purifying or detecting a target protein
WO2009034842A1 (en) Nucleic acid detection method, and nucleic acid detection kit
EP2504348A4 (en) Methods, reagents and kits for detection of nucleic acid molecules
WO2013090386A3 (en) Methods and kits for room temperature in situ detection of a target nucleic acid in a biological sample
WO2012103260A3 (en) High-throughput methods to produce, validate and characterize mmabs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11724450

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011724450

Country of ref document: EP